



## VistaGen Therapeutics to Present at ChinaBio(R) Partnering Forum in Shanghai, China

May 7, 2019

**SOUTH SAN FRANCISCO, CA / ACCESSWIRE / May 7, 2019 / [VistaGen Therapeutics](#)** (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression, social anxiety disorder and other central nervous system (CNS) diseases and disorders with high unmet need, today announced that [Shawn Singh, VistaGen's Chief Executive Officer](#), will present at the 2019 ChinaBio® Partnering Forum held at the Kerry Hotel Pudong in Shanghai, China, on Wednesday, May 8, 2019 at 3:00 p.m. China Standard Time.

For more information regarding the conference, or to schedule a one-on-one meeting with VistaGen's management team, please contact the Company's representative in China, Greg Scott, CEO of ChinaBio at [Greg.Scott@ChinaBio.com](mailto:Greg.Scott@ChinaBio.com).

### About VistaGen

VistaGen Therapeutics is a clinical-stage biopharmaceutical company developing new generation medicines for multiple CNS diseases and disorders with high unmet need. VistaGen's CNS pipeline includes three drug candidates with potential for at-home use, rapid-onset therapeutic benefits and exceptional safety.

For more information, please visit [www.vistagen.com](http://www.vistagen.com) and connect with VistaGen on [Twitter](#), [LinkedIn](#) and [Facebook](#).

### Company Contact

Mark A. McPartland  
VistaGen Therapeutics Inc.  
Phone: +1 (650) 577-3600  
Email: [IR@vistagen.com](mailto:IR@vistagen.com)

### Investor Contact

Valter Pinto / Allison Soss  
KCSA Strategic Communications  
Phone: +1 (212) 896-1254/+1 (212) 896-1267  
Email: [VistaGen@KCSA.com](mailto:VistaGen@KCSA.com)

### Media Contact

Caitlin Kasunich / Lisa Lipson  
KCSA Strategic Communications  
Phone: +1 (212) 896-1241/+1 (508) 843-6428  
Email: [VistaGen@KCSA.com](mailto:VistaGen@KCSA.com)

**SOURCE:** VistaGen Therapeutics

Released May 7, 2019